A rare-disease biotech CEO urged the MHRA to extend beyond its draft rare disease therapy framework, arguing that incentives comparable to the FDA’s Priority Review Voucher (PRV) scheme are missing. Dan Williams of SynaptixBio said the UK framework may cut costs and speed authorizations for early-stage drugs, but without an investor-facing financial lever developers will keep prioritizing US pathways. The discussion references the UK’s proposed investigational marketing authorization concept and contrasts it with the US PRV model, which provides earlier-stage financial support and can be monetized. The critique also arrives after changes in the US that revived the PRV scheme earlier this year.